INIS
thrombin
100%
proteins
69%
plasma
46%
patients
45%
comparative evaluations
35%
values
32%
covid-19
30%
women
29%
risks
29%
evaluation
28%
estrogens
28%
anticoagulants
27%
performance
26%
standardization
23%
reagents
22%
sensitivity
22%
laboratories
22%
reviews
21%
testing
20%
antibodies
20%
receptors
19%
concentration
19%
hemostatics
18%
pregnancy
17%
doses
17%
levels
17%
heparin
17%
thrombosis
16%
data
15%
panels
15%
inflammation
14%
steroids
13%
hormones
13%
range
13%
peaks
13%
biological markers
12%
applications
12%
detection
11%
tissues
11%
in vitro
11%
mutations
11%
wave forms
11%
investigations
10%
assessments
10%
capacity
10%
thromboplastin
10%
vaccines
10%
therapy
10%
interference
9%
screening
9%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombin
47%
Activated Protein C Resistance
18%
Hexadimethrine Bromide
11%
Activated Protein C
11%
Blood Stasis
11%
APC
10%
Contraceptive Agent
10%
Hemostatic Agent
10%
Blood Clotting Disorder
10%
Oral Contraceptive Agent
9%
Venous Thromboembolism
8%
Thromboplastin
8%
Heparin
7%
Estrogen Receptor Positive Breast Cancer
7%
Estetrol
7%
Cytokine
7%
Dexamethasone
7%
Observational Study
7%
Direct Oral Anticoagulant
7%
Tamoxifen
7%
Atrial Fibrillation
7%
Pharmacodynamics
7%
Phospholipid
7%
Infection
7%
SARS Coronavirus
7%
Neutralizing Antibody
7%
Estrogen Receptor
7%
Ultra High Performance Liquid Chromatography
5%
Thrombosis
5%
Keyphrases
Sensitivity Ratio
10%
Resistance Test
9%
Cytokine Response
7%
Polybrene
7%
ST Genesia
7%
Analytical Samples
7%
Performance Stability
7%
Global Coagulation Tests
7%
Estrogen Receptor-positive Breast Cancer
7%
Antigen Test
7%
APC Resistance
7%
COVID-19 Shocks
7%
Critical COVID-19
7%
Regulatory Needs
7%
Unmet Medical Need
7%
Contraceptives
7%
Clinical Investigation
7%
Minimum Interference
7%
Optimal Wavelength
7%
Clot Waveform Analysis
7%
Breast Cancer
7%
Breast Cancer Patients
7%
Activated Protein C
7%
Asundexian
7%
Literature Review Analysis
7%
Omicron Sub-lineages
7%
Postpartum Period
7%
Estrogen Receptor
6%
Anti-spike
5%
Spike Receptor Binding Domain
5%
Factor V Leiden mutation
5%